KR20220029477A - Fusion Protein Comprising IL15 protein, IL15 receptor α protein, Fc domain and IL2 Protein And Uses Thereof - Google Patents

Abstract

The present invention relates to a fusion protein including an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain, and an IL2 protein, and a use thereof, and more specifically, to: a fusion protein including an IL15 protein, an IL15Rα protein, an Fc domain, and an IL2 protein; a dimer including the fusion protein; a composition that is for culturing natural killer (NK) cells and includes the fusion protein or dimer; and a method for culturing NK cells. The fusion protein according to the present invention makes it possible to efficiently proliferate and culture NK cells while maintaining the cytolytic activity of the NK cells and promoting the activation of the NK cells when culturing the NK cells, thereby making it possible to obtain a large number of NK cells without using feeder cells. Therefore, the fusion protein is useful for the commercialization of NK cells into safe cell therapy agents.

Description

Fusion protein comprising IL15 protein, IL15 receptor alpha protein, Fc domain and IL2 protein, and uses thereof {Fusion Protein Comprising IL15 protein, IL15 receptor α protein, Fc domain and IL2 Protein And Uses Thereof}

The present invention relates to a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain and an IL2 protein, and uses thereof, and more particularly, to a fusion protein comprising an IL15 protein, an IL15Rα protein, an Fc domain and an IL2 protein. It relates to a fusion protein and a dimer comprising the fusion protein, a composition for culturing natural killer cells (NK cells) comprising the fusion protein or dimer, and a method for culturing NK cells.

NK cells (natural killer cells; natural killer cells) are lymphoid cells that play an important role in the immune response. It is thought to be an important member of an immune monitoring mechanism that removes abnormal cells that are tumorigenic or are undergoing tumorigenesis in the body. Therefore, studies have been conducted for a long time to effectively utilize these cells for the treatment of tumors and for the removal of virus-infected cells that are supposed to be the source of tumors.

In cell therapy, a sufficient number of cells (cell dose) and repeated administration are very important factors. When a sufficient number of cells are not administered due to insufficient proliferation of NK cells, the biggest problem in clinical application is became Since the number of NK cells present in the body is not large, a technology for mass-producing NK cells while maintaining sufficient efficacy to be used for therapeutic purposes is essential. However, NK cells are not properly proliferated and cultured in large quantities in vitro . Therefore, attention is focused on technology for amplifying and culturing NK cells to a practically useful level, and although many studies are being conducted, it has not yet reached the level applicable to clinical practice.

The development of a technology for obtaining sufficient NK cells to kill target cells by once culture-amplifying NK cells obtained from a donor in vitro is in progress. In addition to IL2 used for conventional T cell proliferation/activation, IL15 (Dunne J et al ., Immunology, vol. 167:3129. 2001), LPS (MR Goodier et al ., Immunology 165:139, 2000), CD3 stimulating OKT-3 antibody (Condiotti R, et al ., Experimental Hematology 29:104, 2001) in single/complex form There have been studies to proliferate NK cells by using them as However, they only found new proliferation materials in the form of modifications and developments to the classically used IL2 use, but did not suggest a breakthrough proliferation method.

As an effective method for increasing NK cell viability and in vitro proliferation, there is a method of co-culturing with feeder cells. Feeder cells commonly used for NK proliferation include irradiated PBMCs, Epstein-Ban virus transformed lymphoblastic cell line (EBC-LCL), genetically modified K562 cells that constitutively express IL15 or 21, and other irradiated tumor cell lines. (Berg, M., et al ., Cytotherapy. 2009; 11(3):341-55; Baek, H J., et al ., Anticancer Res. 2013; 33(5):2011-9) . Co-culture with feeder cells increases NK cell viability and proliferation by 1,000 to 50,000-fold (Denman, CJ, et al ., PLoS ONE. 2012;7(1):e30264).

Meanwhile, cases in which NK cells are amplified using a tumor cell line as a feeder cell have been reported. Although CTV-1, a leukemia cell line, was used as feeder cells, there was little improvement in proliferation (J Immunol., 178(1): p85-94, 2007), and when cultured for 21 days using EBV-LCL, NK cells has been reported to proliferate 490-fold (Cytotherapy, 11(3): p341-355, 2009). However, all of these results used methods that were not suitable for ensuring safety important for clinical applications, such as using cancer cell lines as feeder cells, and priming against specific cancer cells by using a specific cancer cell line rather than a normal cell as a feeder cell. (priming) It has a limit in producing NK cells to which specificity is imparted.

Accordingly, various attempts have been made to culture NK cells in a 'feeder cell free' method that does not use feeder cells. If a cytokine such as IL2, IL12, IL15, IL18, IL21 or nicotinamide is sufficiently provided, it can be cultured without feeder cells. The generated NK cells show increased cytotoxicity compared to freshly isolated NK cells, but can only proliferate 100 to 300 fold (Childs, RW et al ., Hematology Am Soc Hematol Educ Program. 2013;2013(1)). :234-46). The reason proliferation is limited is due to telomere loss and aging (Denman, CJ, et al ., PLoS ONE. 2012;7(1):e30264). Residual IL2 can also cause serious side effects in patients (Ni, J., et al ., Oncolmmunology 2013; 2:4, e23811).

In addition, to increase the proliferation of immune cells, including NK cells, using IL15 and IL15 receptor alpha (IL15Rα) (US 8,124,084 B), or using IL2, IL15 (or IL12, IL18) and anti-NKp46 antibodies to NK Although there is an example in which cells were cultured (JP 6073417 B), it still did not show a significantly increased NK cell proliferation rate.

Accordingly, the present inventors made diligent efforts to develop an NK cell culture method that can further increase the proliferation and survival rate of NK cells while culturing in a 'feeder cell free' method, and as a result, IL15 protein, IL15 receptor alpha (IL15Rα) protein, Fc In the case of culturing NK cells using a fusion protein comprising a domain and an IL2 protein, it is possible to significantly increase the proliferation and cell survival of NK cells while maintaining the killing ability of NK cells, and effectively promote the activation of NK cells. It was confirmed that it can be done, and the present invention was completed.

The information described in the background section is only for improving the understanding of the background of the present invention, and it does not include information forming prior art known to those of ordinary skill in the art to which the present invention pertains. may not be

It is an object of the present invention to provide a fusion protein capable of effectively culturing NK cells while ensuring safety.

Another object of the present invention is to provide a NK cell culture composition and NK cell culture method comprising the fusion protein.

Another object of the present invention is to provide a composition for treating cancer, immune disease, or infectious disease comprising the NK cells prepared by the culturing method.

Another object of the present invention is a method for preventing or treating cancer, immune disease or infectious disease using the NK cells prepared by the culturing method, the use of the NK cells for preventing or treating cancer, immune disease or infectious disease, and cancer, immunity An object of the present invention is to provide the use of the NK cells for the manufacture of a medicament for the prevention or treatment of a disease or an infectious disease.

In order to achieve the above object, the present invention provides a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain, and an IL2 protein.

The present invention also provides a polynucleotide encoding the fusion protein, a vector containing the polynucleotide, a transformed cell into which the vector is introduced, and a method for producing a fusion protein comprising the step of culturing the transformed cell.

The present invention also provides a fusion protein dimer in which the two fusion proteins are bound.

The present invention also provides a composition for culturing natural killer cells comprising the fusion protein or fusion protein dimer, and culturing the NK cells in a medium containing the composition NK cells (natural killer cells) A culture method is provided.

The present invention also provides a composition for treating cancer, immune disease, or infectious disease comprising the NK cells prepared by the culturing method.

The present invention also provides a method for preventing or treating cancer, an immune disease or an infectious disease comprising administering the NK cells prepared by the culturing method, the use of the NK cells for preventing or treating cancer, an immune disease or an infectious disease, and Provided is the use of the NK cells for the manufacture of a medicament for the prophylaxis or treatment of cancer, immune disease or infectious disease.

The fusion protein according to the present invention enables efficient proliferation and culture while maintaining the killing ability of NK cells and promoting activation in culturing NK cells, so that a large number of NK cells can be obtained without using feeder cells. This is useful for commercialization of cell therapy products with secured safety.

1 is a schematic diagram of the structure of a fusion protein according to the present invention.
2 is a diagram showing the results of FACS analysis of CD3-CD56+ NK cells isolated from PBMC.
3 is a culturing method using Comparative Examples (1, 2, 3) for CD3-CD56+ PBMC cells and a fusion protein according to the present invention (Experimental Examples 1-1, 1-2, 1-3, 2-1, 2-2, 2-3) is a graph comparing the survival rate and proliferation rate of cells cultured for 18 days according to the culture method used.
4 to 6 show comparative examples (1, 2, 3) and fusion proteins according to the present invention (Experimental Examples 1-1, 1-2, 1-3, 2-1, 2-2, 2-3) It is a graph confirming the purity of the cells cultured for 18 days (FIG. 4), an activity marker, an inhibitory marker, and a marker involved in cancer killing (FIGS. 5 and 6) using flow cytometry.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is those well known and commonly used in the art.

Immunotherapy, which is emerging recently, is a treatment that uses the body's own immune system to minimize damage to normal cells and remove cancer cells more specifically. Virus immunotherapy, nanotechnology immunotherapy, etc.) is being actively researched. Among these, immune cell therapy is a treatment for lymphocytes obtained from the patient's blood, natural killer cells (NK cells), natural killer T cells (natural killer T cells), T cells, B cells, dendritic cells, etc. It is a method of treating cancer, etc. by increasing the number of cells, enhancing their functions in vitro , and returning them to the patient's body. Therapeutic treatment using these immune cells has a good effect on immune response modulation treatment and is evaluated to be excellent in toxicity and safety. Among them, NK cells are important cells responsible for innate immunity, and unlike T cells, they mature in the liver and bone marrow. In particular, it has a function of self-identifying and killing abnormal cells such as virus-infected cells or tumor cells.

A method of massively proliferating NK cells and culturing NK cells with enhanced activity, which can resolve immune rejection and provide patient-specific cell therapy as a cell therapy for the treatment of intractable diseases such as cancer this is required

In one embodiment of the present invention, when culturing NK cells using a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain and an IL2 protein, and a composition for culture comprising the same, cytokines such as IL2 Compared to the previously known NK cell culture method of culturing using Cain, it can significantly increase the proliferation and cell survival of NK cells while maintaining the killing ability of NK cells, and can effectively promote the activation of NK cells. was confirmed. This suggests that NK cells can be cultured more effectively, and safety can be secured because NK cells are cultured in a ‘feeder cell free’ method, which suggests that they can be usefully used as cell therapy agents.

Accordingly, in one aspect, the present invention relates to a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain, and an IL2 protein.

In the present invention, the IL15 protein may include the amino acid sequence shown in SEQ ID NO: 1, and the IL15 receptor alpha (IL15Rα) protein comprises the amino acid sequence shown in SEQ ID NO: 3 can, but is not limited thereto.

IL15 (Interleukin 15) is structurally similar to IL2 secreted by mononuclear phagocytes (and several other cells) after infection with a virus or after indirect stimulation by cells recognized as attenuated or non-self It is a cytokine with IL15 and IL2 bind to two shared receptors of the common gamma chain (γc, CD132) and the IL2 receptor B chain (IL-2Rβ, CD122), as well as the IL2 receptor alpha (IL2Rα; CD25) or IL2 receptor, an alpha chain receptor unique to each cytokine. It exerts cellular signaling functions through binding to a trimeric complex composed of IL15 receptor alpha (IL15Rα; CD215).

As is known in the art, the IL15Ra protein contains the "sushi domain", which is the shortest region of the receptor that retains IL15 binding activity. Accordingly, a fusion protein including the entire IL15Rα protein can be prepared, but preferably a fusion protein including a sushi domain can be prepared.

In the present invention, "IL15 protein" refers to a full-length IL15 or IL15 fragment, and "IL15Rα protein" refers to a full-length IL15Rα or IL15Rα fragment.

As used herein, the term “IL15 fragment” or “IL15Rα fragment” refers to a cleaved form of IL15 or IL15Rα, and the IL15Rα fragment may be characterized as a sushi domain of IL15Rα.

In the present invention, the Fc domain may be characterized in that it comprises an immunoglobulin heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3).

In the present invention, the Fc (heavy chain constant region) domain may be characterized in that it further comprises a hinge domain.

In the present invention, the immunoglobulin may be characterized in that it is IgG, IgA, IgE, IgD or IgM.

Preferably, the Fc domain may be an IgG Fc domain, for example, an IgG1, IgG2, IgG3 or IgG4 Fc domain, more preferably, an IgG4 Fc domain, but is not limited thereto.

In addition, the Fc domain of the immunoglobulin may be a wild-type Fc domain as well as an Fc domain variant. In addition, the term "Fc domain variant" as used herein is different from the glycosylation pattern of the wild-type Fc domain, increased sugar chains compared to the wild-type Fc domain, decreased sugar chains compared to the wild-type Fc domain, or the sugar chains are removed ( It may be in a deglycosylated form. It also includes an aglycosylated Fc domain. The Fc domain or variant may have a number of sialic acid, fucosylation, and glycosylation adjusted through culture conditions or genetic manipulation of the host.

In the present invention, the Fc domain may be characterized in that it comprises the amino acid sequence represented by SEQ ID NO: 5, but is not limited thereto.

In the present invention, the IL2 protein may be characterized as a wild-type or mutant.

Interleukin 2 (IL2), also called T-cell growth factors (TCGF), is a globular glycoprotein that plays a central role in lymphocyte production, survival and homeostasis. The protein size of IL2 is 15.5 kDa to 16 kDa, and consists of 133 amino acids. IL2 mediates various immune actions by binding to the IL2 receptor composed of three individual subunits.

In addition, IL2 is mainly synthesized by CD4+ helper T cells among activated T cells. IL2 stimulates proliferation and differentiation of T cells, produces cytotoxic T lymphocytes (CTLs) and cytotoxic cells of peripheral blood lymphocytes and lymphokine activated killer cells (LAK cells) induce differentiation into

As used herein, "IL2 protein" refers to a full-length IL2 or IL2 fragment, and "IL2 fragment" refers to a truncated form of IL2.

In the present invention, the wild-type IL2 protein may include the amino acid sequence shown in SEQ ID NO: 7.

In the present invention, the IL2 protein variant may include the amino acid sequence shown in SEQ ID NO: 8, including R38A and F42A mutations in the amino acid sequence of SEQ ID NO: 7, but is not limited thereto.

In the present invention, the fusion protein uses the Fc domain as a linker and IL15 is directly linked to the N-terminus and C-terminus of the fusion protein or IL15Rα and IL2 are linked by a linker, or IL2 and IL15 are linked directly or by a linker. It may have a structure in which IL15Rα is linked ( FIG. 1 ). The N-terminus or C-terminus of the Fc domain and IL15Rα or IL2 may optionally be connected by a linker peptide.

Specifically, the fusion protein may be characterized in that it consists of the following structural formula (I):

N'-X-[Linker(1)]l-Y-[Linker(2)]n-Fc domain-[Linker(3)]m-Z-C' (Structural formula (I))

here,

N' is the N-terminus of the fusion protein, C' is the C-terminus of the fusion protein,

X is an IL15 protein, Y is an IL15 receptor alpha (IL15Rα) protein, Z is an IL2 protein,

Linker (1), linker (2) and linker (3) are peptide linkers,

l, n and m are each independently O or 1.

In the present invention, the linker connects two proteins. One embodiment of the linker may include 1 to 100 amino acids, albumin or a fragment thereof, or the Fc hinge domain of an immunoglobulin.

In the present invention, the linker (1) and linker (3) may consist of 1 to 100 consecutive amino acids, 5 to 50 consecutive amino acids, or 5 to 30 amino acids. In one embodiment of the present invention, the linker (1) and the linker (3) may be (G4S)n, where n is an integer from 1 to 10, that is, 1, 2, 3, 4, 5, It may be 6, 7, 8, 9 or 10, but is not limited thereto.

In the present invention, the linker (2) may consist of 1 to 100 consecutive amino acids, 5 to 80 consecutive amino acids, 20 to 60 consecutive amino acids, or 25 to 50 consecutive amino acids. In one embodiment of the present invention, the linker (2) may include (G4S)n and an immunoglobulin hinge, wherein n is an integer from 1 to 10, that is, 1, 2, It may be 3, 4, 5, 6, 7, 8, 9 or 10, but is not limited thereto.

In the present invention, preferably, the linker (1) comprises the amino acid sequence shown in SEQ ID NO: 2, the linker (2) comprises the amino acid sequence shown in SEQ ID NO: 4, the linker (3) may be characterized as comprising the amino acid sequence represented by SEQ ID NO: 6, but is not limited thereto.

In the present invention, the fusion protein may be characterized in that it comprises an amino acid sequence represented by SEQ ID NO: 9 or SEQ ID NO: 10.

In the present specification, the fusion protein comprising IL15, IL15Rα, Fc domain and IL2 wild-type (WT) according to the present invention was named 'fusion protein A' (Table 1), including IL15, IL15Rα, Fc domain and IL2 variants The fusion protein was named 'fusion protein B' (Table 2).

order
number component Sequence Number of
amino acids 13 Albumin Signal Sequence MKWVTFISLLFLFSSAYS 18 One Human IL15 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS 114 (N-Gly site: 1) 2 Linker 1 GGGGSGGGGSGGGGSGGGGS 20 3 Human IL15Ra Sushi domain ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPS 78 (N-Gly site: 1) 4 Linker 2 GGGGSGGGGSGGGGSAESKYGPPCPPCP 28 5 IgG4 Fc APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYFSTTPPSQEEMTKNQVSLTSRDKGFYPSDIVLSSRVSLSDALKFYPSDIVLSSR 216 (N-Gly site: 1) 6 Linker 3 GGGGS 5 7 Human IL2 _WT APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT 133 (O-Gly site: 1) 9 Fusion Protein A NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSGGGGSGGGGSGGGGSGGGGSITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT 594 (Monomer) 11 Fusion Protein A GCCACCATGAAGTGGGTCACCTTCATCTCCCTGCTGTTTCTGTTCTCCTCCGCCTACTCCAACTGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGATGTGCACCCTTCTTGCAAAGTGACCGCTATGAAGTGCTTCCTGCTGGAACTGCAAGTGATCTCCCTGGAATCCGGCGACGCCTCTATCCACGATACCGTGGAAAACCTGATCATCCTGGCCAACAACTCCCTGTCCTCCAACGGCAATGTGACCGAGTCTGGCTGCAAAGAGTGCGAGGAACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCCTTCGTCCACATCGTGCAGATGTTCATCAACACCTCTGGCGGCGGAGGAAGTGGTGGCGGAGGATCTGGCGGTGGTGGTTCTGGCGGAGGCGGATCTATTACCTGTCCACCTCCTATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACATCTTCTCTGACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCTCACTGGACCACACCTAGCCTGAAGTGCATCAGAGATCCCGCTCTGGTCCATCAGAGGCCTGCTCCTCCAAGCGGTGGTGGTGGAAGCGGAGGTGGCGGATCAGGTGGTGGCGGTTCTGCTGAGTCTAAGTACGGACCTCCTTGTCCACCTTGTCCTGCTCCAGAAGCTGCTGGCGGACCAAGCGTTTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTCGATGTGTCTCAAGAGGACCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGT CCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCTAAGGGCCAGCCTCGGGAACCTCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGTCCAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCCTTTTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCTGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCTCTTGGAGGCGGTGGCGGAAGTGCTCCTACCTCCAGCTCTACCAAGAAAACCCAGCTGCAGTTGGAGCATCTGCTGCTGGACCTCCAGATGATCCTGAATGGCATCAACAATTACAAGAACCCCAAGCTGACCCGGATGCTGACCTTCAAGTTCTACATGCCCAAGAAGGCCACCGAGCTGAAGCACCTCCAGTGCCTGGAAGAGGAACTGAAGCCCCTGGAAGAAGTGCTGAATCTGGCCCAGTCCAAGAACTTCCACCTGAGGCCTCGGGATCTGATCTCCAACATCAATGTGATCGTGTTGGAGCTGAAGGGCTCCGAGACAACCTTCATGTGCGAGTACGCCGACGAGACAGCCACCATCGTGGAATTTCTGAACCGGTGGATCACCTTCTGCCAGTCCATCATCTCCACACTGACCTGATGACTCGAGA

order
number component Sequence Number of
amino acids 13 Albumin Signal Sequence MKWVTFISLLFLFSSAYS 18 One Human IL15 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS 114 (N-Gly site: 1) 2 Linker 1 GGGGSGGGGSGGGGSGGGGS 20 3 Human IL15Rα Sushi domain ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPS 78
(N-Gly site: 1) 4 Linker 2 GGGGSGGGGSGGGGSAESKYGPPCPPCP 28 5 IgG4 Fc APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYFSTTPPSQEEMTKNQVSLTCLDKGFYPSDIVLSSRVESRDALKGFFYPSDIVLSSR 216 (N-Gly site: 1) 6 Linker 3 GGGGS 5 8 Human IL2 _{R38A F42A} APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT 133 (O-Gly site: 1) 10 Fusion Protein B NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSGGGGSGGGGSGGGGSGGGGSITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT 594 (Monomer) 12 Fusion Protein B GCCACCATGAAATGGGTCACCTTTATCTCCCTGCTGTTCCTGTTCTCCTCCGCCTACTCCAACTGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCACCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAACTGCAAGTGATCTCCCTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAAAACCTGATCATCCTGGCCAACAACTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAAGAGTGCGAGGAACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCCTTCGTGCACATCGTGCAGATGTTCATCAACACCTCTGGCGGCGGAGGATCTGGCGGAGGTGGAAGCGGAGGCGGAGGTAGCGGTGGTGGTGGATCTATCACATGCCCTCCACCTATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGGGACCCCGCTCTGGTTCATCAGAGGCCTGCTCCACCTAGTGGTGGCGGTGGTAGTGGCGGAGGCGGTTCAGGTGGCGGCGGATCTGCTGAGTCTAAGTACGGACCTCCTTGTCCACCTTGTCCTGCTCCAGAAGCTGCTGGCGGCCCTTCCGTGTTTCTGTTCCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGT CCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGAACCCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTCCCTGTCTCTGTCCCTTGGAGGTGGTGGTGGCTCTGCTCCTACCTCCTCCAGCACCAAGAAAACCCAGCTGCAGTTGGAGCATCTGCTGCTGGACCTCCAGATGATCCTGAATGGCATCAACAATTACAAGAACCCCAAGCTCACCGCCATGCTGACCGCCAAGTTCTACATGCCCAAGAAGGCCACCGAGCTGAAGCACCTCCAGTGCCTGGAAGAGGAACTGAAGCCCCTGGAAGAAGTGCTGAATCTGGCCCAGTCCAAGAACTTCCACCTGAGGCCTCGCGACCTGATCTCCAACATCAATGTGATCGTGTTGGAGCTGAAGGGCTCCGAGACAACCTTCATGTGCGAGTACGCCGACGAGACAGCTACCATCGTGGAATTTCTGAACCGGTGGATCACCTTCTGCCAGTCCATCATCTCCACACTGACCTAATAACTCGAG

In another aspect, the present invention provides a polynucleotide encoding a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain and an IL2 protein, a vector comprising the polynucleotide, and a transformed cell into which the vector is introduced is about

When the nucleotide sequence is prepared by chemical synthesis, a synthesis method well known in the art, for example, the method described in the literature (Engels and Uhlmann, Angew Chem IntEd Engl, 37:73-127, 1988) can be used, and triester, phosphite, phosphoramidite and H-phosphate methods, PCR and other autoprimer methods, and oligonucleotide synthesis methods on a solid support.

In the present invention, the polynucleotide may include a nucleic acid sequence represented by SEQ ID NO: 11 or SEQ ID NO: 12, but is not limited thereto.

Meanwhile, the polynucleotide may additionally include a signal sequence or a leader sequence. As used herein, the term “signal sequence” refers to a nucleic acid encoding a signal peptide that directs secretion of a target protein. The signal peptide is cleaved after translation in the host cell. Specifically, the signal sequence of the present invention is a nucleotide encoding an amino acid sequence that initiates the movement of a protein through the ER (endoplasmic reticulum) membrane. Signal sequences useful in the present invention include antibody light chain signal sequences, such as antibody 1418 (Gillies et al, J Immunol Meth 1989 125: 191-202), antibody heavy chain signal sequences, such as MOPC141 antibody heavy chain signal sequence (Sakano et al.) al, Nature, 1980 286: 676-683) and other signal sequences known in the art (see, eg, Watson et al, Nucleic Acid Research, 1984 12:5145-5164).

In the present invention, the signal peptide may include the amino acid sequence represented by SEQ ID NO: 13.

In the present invention, the vector can be introduced into a host cell, recombination and insertion into the host cell genome. or said vector is understood as a nucleic acid means comprising a polynucleotide sequence capable of spontaneously replicating as an episome. Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors and analogs thereof. Examples of viral vectors include, but are not limited to, retroviruses, adenoviruses, and adeno-associated viruses.

Specifically, the vector may be plasmid DNA, phage DNA, etc., commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), E. coli-derived plasmids (pYG601BR322, pBR325, pUC118, pUC119, etc.), Bacillus subtili plasmids (pUB110, pTP5, etc.), yeast-derived plasmids (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), animal virus vectors (retroviruses) ), adenovirus, vaccinia virus, etc.), insect virus vectors (baculovirus, etc.). Since the vector exhibits different protein expression levels and modifications depending on the host cell, it is preferable to select and use the most suitable host cell for the purpose.

As used herein, the term "gene expression" or "expression" of a target protein is understood to mean transcription of a DNA sequence, translation of an mRNA transcript, and secretion of a fusion protein product or a fragment thereof. A useful expression vector may be RcCMV (Invitrogen, Carlsbad) or a variant thereof. The expression vector contains a human cytomegalovirus (CMV) promoter to promote continuous transcription of the target gene in mammalian cells, and a bovine growth hormone polyadenylation signal sequence to increase the stable-state level of RNA after transcription. can do.

In the present invention, the host cell of the transformed cell may include, but is not limited to, prokaryotic cells, eukaryotic cells, mammalian cells, plants, insects, fungi or cells of cellular origin. E. coli may be used as an example of the prokaryotic cell. In addition, yeast may be used as an example of eukaryotic cells. In addition, CHO cells, F2N cells, CSO cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, HEK 293 cells or HEK293T cells may be used as the mammalian cells. , but is not limited thereto, and any cell that can be used as a mammalian host cell known to those skilled in the art is available.

In addition, when introducing the expression vector into a host cell, the CaCl ₂ precipitation method, the CaCl ₂ precipitation method using a reducing material called DMSO (dimethyl sulfoxide), the Hanahan method, electroporation (electroporation), calcium phosphate precipitation method to increase the efficiency , protoplast fusion method, agitation method using silicon carbide fiber, agrobacterium mediated transformation method, transformation method using PEG, dextran sulfate, lipofectamine and drying/inhibition mediated transformation method, etc. can be used.

As described above, in order to optimize the properties of the fusion protein or for other purposes, the glycosylation-related gene possessed by the host cell is manipulated through a method known to those skilled in the art, and the sugar chain pattern (e.g., sialic acid) of the fusion protein is manipulated. , fucosylation, glycosylation) can be adjusted.

In another aspect, the present invention relates to a method for producing a fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain, and an IL2 protein, comprising culturing the transformed cell.

Specifically, the manufacturing method comprises the steps of i) culturing the transformed cells to obtain a culture; and ii) recovering the fusion protein from the culture.

The method of culturing the transformed cells may be performed using a method widely known in the art, and specifically, the culture is a batch process or injection batch or repeated fed batch process (fed batch or repeated fed batch process) It can be cultured in a continuous manner, but is not limited thereto.

In another aspect, the present invention relates to a fusion protein dimer in which the two fusion proteins are combined.

In the present invention, the bond between the fusion proteins constituting the dimer of the fusion protein may be formed by a disulfide bond (S-S) by cysteine (C) present in the linker, but is not limited thereto.

The fusion proteins constituting the dimer may be the same, but may be different fusion proteins. Preferably, the fusion protein dimer may be characterized as a homodimer, but is not limited thereto.

In the present invention, the fusion protein dimer may be prepared by binding a monomer fusion protein prepared by the method for preparing the fusion protein by a disulfide bond, or encoding the fusion protein dimer. It can be prepared by the same method as the above fusion protein production method using a vector containing a polynucleotide or a transformed cell.

In another aspect, the present invention comprises the step of culturing NK cells in a medium containing the fusion protein or a composition for culturing natural killer cells comprising the fusion protein dimer and the composition for culturing the NK cells It relates to a method for culturing natural killer cells (NK cells).

In the present invention, the NK cells may be derived from, for example, mammals, humans, monkeys, pigs, horses, cattle, sheep, dogs, cats, mice or rabbits. The NK cells may be obtained from a normal person or a cancer patient. The NK cells may be isolated from blood or PBMC.

In the present invention, the culture may be for NK cell proliferation or NK cell activation. The proliferation of the NK cells means an increase in the number of cells, and can be mixed with growth. Activation of the NK cells means that the above-mentioned NK cells perform their functions, and it may be characterized by high expression of surface antigens of CD16, DNAM1, NKG2C, NKG2D, NKp46, CCR5, or a combination thereof. The NK cell activation means that NK cells perform their functions, and may be characterized by low expression of surface antigens of NKG2A, TIGIT, CD25, CD57, CD96, or a combination thereof.

The surface antigen property has the same meaning as an immunological property, and a cell surface label (eg, staining the cell with a tissue-specific or cell-marker specific antibody) using a technique such as flow cytometry or immunocytochemistry; or by observing cell surface markers using light microscopy or confocal microscopy, or using techniques well known in the art such as polymerase chain reaction (PCR), or gene-expression profiling. This can be confirmed by measuring the change.

In relation to the cell marker (marker), the “positive or +” may mean that the marker is present in a larger amount or at a higher concentration compared to other cells as a reference. A cell can be positive for a marker if that marker can be used to distinguish the cell from one or more other cell types because it is present inside or on the cell's surface. It may also mean that the cell has the label in an amount sufficient to generate a signal, eg, a signal of a cytometer, at a value greater than the background value. For example, a cell can be detectably labeled with an antibody specific for CD56, and if the signal from this antibody is detectably greater than a control (eg, background value), the cell is "positive for CD56." " or "CD56+". The term "negative or -" may mean that even when an antibody specific for a specific cell surface label is used, the label cannot be detected compared to the background value. For example, if cells cannot be detectably labeled with an antibody specific for CD3. Those cells can be labeled “CD3 negative” or “CD3-”.

In the present invention, the NK cell culture composition may further include any one selected from the group consisting of a medium, serum, supplement, and combinations thereof.

The NK cell culture medium may contain amino acids, sugars, inorganic salts or vitamins. Preferably, the cell culture medium may include all of amino acids, sugars, inorganic salts and vitamins.

As used herein, the term “cell culture medium” refers to a medium used for culturing cells, specifically, a medium for culturing NK cells, more specifically, CD3-CD56+ cells. It contains components required by cells for cell growth and survival in vitro, or contains components that support cell growth and survival. Specifically, the ingredients may be vitamins, essential or non-essential amino acids, and trace elements. The medium may be a medium used for culturing cells, preferably eukaryotic cells, more preferably NK cells.

In the present invention, the amino acid component is glycine, L-alanine, L-valine, L-leucine, L-isoleucine, L-threonine, L-serine, L-cysteine, L-methionine, L-aspartic acid, L- Asparagine, L-glutamic acid, L-glutamine, L-lysine, L-arginine, L-histidine, L-phenylalanine, L-tyrosine, L-tryptophan, L-proline, β-alanine, γ-aminobutyric acid, ornithine, It may be at least one amino acid selected from the group consisting of citrulline, homoserine, triiodotyrosine, thyroxine and deoxyphenylalanine, or a combination thereof.

The vitamin component is at least one vitamin selected from the group consisting of biotin, D-calcium pantothenate, folic acid, niacinamide, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride, vitamin B12, choline chloride, i-inositol and ascorbic acid, or It may be a combination thereof, and preferably, at least one vitamin selected from the group consisting of i-inositol, thiamine hydrochloride, niacinamide and pyridoxine hydrochloride, or a combination thereof.

The inorganic salt component is calcium chloride (CaCl ₂ ) (anhydrous), copper sulfate pentahydrate (CuSO ₄ -5H ₂ O), ferric sulfate heptahydrate (FeSO ₄ -7H ₂ O), magnesium chloride (anhydrous), magnesium sulfate (MgSO ₄ ) (anhydrous), potassium chloride (KCl), sodium chloride (NaCl), disodium hydrogen phosphate (Na ₂ HPO ₄ ), sodium hydrogen phosphate monohydrate (NaH ₂ PO ₄ -H ₂ O), zinc sulfate heptahydrate (ZnSO ₄ -7H) ₂ O), ferric nitrate nonahydrate (Fe(NO ₃ ) ₃ ·9H ₂ O), and sodium hydrogen carbonate (NaHCO ₃ ) It may be at least one inorganic salt selected from the group consisting of, or a combination thereof.

The other ingredients include D-glucose (dextrose), sodium pyruvate, hypoxanthine Na, thymidine, linoleic acid, lipoic acid, adenosine, cytidine, guanosine, uridine, 2'-deoxyadenosine, 2'- It may be at least one other component selected from the group consisting of deoxycytidine HCl and 2'-deoxyguanosine, or a combination thereof.

In the present invention, the composition for cell culture may further include an antibody for activating natural killer cells. As the antibody for the activity, an anti-CD3 antibody, an anti-CD2 antibody, an anti-CD335 antibody, etc. may be used alone or in two or more types, but the present invention is not particularly limited thereto. It may also include beads to which the antibody for activating natural killer cells is bound. In addition, a fusion protein comprising two or more types of antibodies or variable region fragments for activating natural killer cells may be used.

In the present invention, the medium is DMEM (Dulbecco's Modified Eagle's Medium), EDM (Endothelial differentiation medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, a- A conventional medium for animal cell culture, such as a-Minimal Essential Medium (MEM), Glasgow's Minimal Essential Medium (G-MEM), Iscove's Modified Dulbecco's Medium, AIM-V Medium, X-vivo™ 15 Medium, or NK MACS Medium, may be used. can

In the present invention, the "serum" refers to a transparent supernatant separated from the blood after the blood is completely coagulated. In addition, serum must be added to the synthetic medium for culturing animal cells, and it is common to use bovine, horse, or human serum. In the case of bovine-derived serum, bovine fetal bovineserum (FBS), bovine newborn bovine serum, calf serum, bovine serum, etc. may be used depending on the blood sampling period. . In the case of human-derived serum, human serum from a donor whose blood type is AB may be used, and human AB serum capable of minimizing immune reactivity may be used because it does not have antibodies to A and B blood group antigens. In addition, as an alternative to serum, CTS Immune Cell SR, etc. can be used.

In the present invention, the “supplement” may use GlutaMAX (Gibco®), an L-Glutamine substitute, in order to improve stability and cell activity in cell culture. In addition, the supplement may be NK MACS supplement (Miltenyi Biotec, 130-113-102).

In the present invention, the NK cell culture composition may contain the fusion protein or the fusion protein dimer at a concentration of 1 nM to 500 nM. Specifically, 1 nM to 500 nM, preferably 1 nM to 300 nM, more preferably 1 nM to 150 nM concentration may be included, but is not limited thereto. In one embodiment of the present invention, the fusion protein dimer was included at a concentration of 1 nM or 50 nM.

In the present invention, the NK cell culture method is

(a) isolating cells that do not express CD3 from peripheral blood mononuclear cells (PBMCs); (b) separating the cells expressing CD56 from the cells isolated in step (a); and (c) culturing the cells isolated in step (b) in the presence of a composition comprising the fusion protein or fusion protein dimer;

In the present invention, the culturing method may further comprise the step of obtaining PBMCs from peripheral blood before the step of culturing. Separating CD3 non-expressing (CD3-) NK cells from the obtained PBMC, separating CD56-expressing (CD56+) NK cells, and culturing the isolated NK cells in the presence of the fusion protein or fusion protein dimer can be characterized as

In the present invention, the culture method can be performed using a method widely known in the art. Specifically, in the step of culturing the isolated cells, the culture temperature may be 27°C to 40°C, preferably 30°C to 37°C. In one embodiment of the present invention, cultured at a temperature of 37 ℃. In addition, during culturing in the step of culturing the isolated cells, the CO ₂ concentration condition may be 1% to 10%, and preferably, it may be cultured under 5% CO ₂ conditions.

In another aspect, the present invention relates to a composition for preventing or treating cancer, immune disease, or infectious disease comprising NK cells (natural killer cells) prepared by the NK cell culture method.

In another aspect, the present invention relates to a method for preventing or treating cancer, immune disease, or infectious disease, comprising administering the NK cells prepared by the culturing method.

In another aspect, the present invention relates to the use of the NK cells prepared by the culturing method for the prevention or treatment of cancer, immune disease or infectious disease.

In another aspect, the present invention relates to the use of the NK cells prepared by the culturing method for the manufacture of a medicament for the prevention or treatment of cancer, immune disease, or infectious disease.

In the present invention, the term 'cancer' is used in the same sense as 'tumor', and the composition for prevention or treatment according to the present invention is applicable to all types of cancer including solid cancer and blood cancer. Unlike blood cancer, solid cancer refers to cancer formed by forming a lump in an organ, and cancer occurring in most organs corresponds to this. Cancers that can be treated using the fusion protein and NK cells according to the present invention are not particularly limited, and gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid cancer leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma, and the like, but is not limited thereto.

In the present invention, the 'immune disease' is a disease caused by an abnormal immune response, for example, may be characterized as an autoimmune disease, transplant rejection, or arthritis, but is not limited thereto. The autoimmune disease is, for example, Crohn's disease, erythematosus, atopy, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes, lupus, chronic fatigue syndrome, fibromyalgia, hypothyroidism and hyperthyroidism, scleroderma , Behcet's disease, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, Meniere's syndrome, Guilian-Barre syndrome, Sjogren's syndrome, vitiligo, endometriosis, psoriasis, systemic scleroderma, It may be asthma or ulcerative colitis, but is not limited thereto. The transplant rejection may be allograft rejection or graft-versus-host disease (GVHD).

In the present invention, an 'infectious disease' is a disease caused by infection with a virus or a pathogen, and is a concept including all diseases that can be transmitted and infected through respiratory, blood, and skin contact. Non-limiting examples of such infectious diseases include hepatitis B and C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza, etc., but is limited thereto not.

The prophylactic or therapeutic composition according to the present invention may contain a pharmaceutically effective amount of the NK cells prepared by the above culture method alone, or may contain one or more pharmaceutically acceptable carriers, excipients or diluents. In the above, the pharmaceutically effective amount refers to an amount sufficient to prevent, improve, and treat symptoms of cancer, immune disease, or infectious disease.

The "pharmaceutically acceptable" means that when it is physiologically acceptable and administered to a human, it does not usually cause an allergic reaction such as gastrointestinal disorder, dizziness, or a reaction similar thereto. Examples of such carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, fillers, anti-agglomeration agents, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.

In addition, the composition of the present invention may include one or more known active ingredients having a therapeutic effect on cancer, immune disease, or infectious disease together with the NK cells prepared by the culturing method.

The compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. Formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, or sterile powders.

The composition of the present invention can be administered through several routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient depends on several factors such as the route of administration, the age, sex, weight and severity of the patient. It may be appropriately selected according to the present invention, and the composition for prophylaxis or treatment according to the present invention may be administered in combination with a known compound having an effect of preventing, improving or treating symptoms of cancer, immune disease, or infectious disease.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

Example 1: CD3- CD56+ NK Cell preparation and culture

Example 1-1: CD3- CD56+ NK Preparation of cells

(1) STEP 1: LRS from the chamber PBMC Separation

1) An LRS chamber was purchased from the Red Cross Southern Blood Center.

2) Recover the main raw material using 30mL of cliniMACS buffer in the LRS Chamber.

3) Overlay 30mL of dilution of main ingredient on 15mL of Ficoll paque.

4) Wash the tube containing the dilution of the main ingredient with CliniMACS buffer and overlap it with 15mL of ficoll paque.

5) Centrifuge at 400×g at room temperature for 30 minutes with break off.

6) Recover all of the supernatant including the PBMC layer.

(2) STEP 2: from PBMC Remove CD3

1) Count the number of PBMC cells recovered in STEP 1.

2) Centrifuge the cell suspension at 340×g for 10 minutes. Remove the supernatant completely.

3) Resuspend the cell pellet in 80 μL of CliniMACS buffer (a solution containing pH 7.2, 0.5% human serum albumin (HSA) and 2 mM EDTA) per 10 ⁷ total cells.

4) Add 20 μL of CD3 MicroBeads (Miltenyi Biotec, Cat#130-050-101) per 10 ⁷ total cells.

5) Mix well and incubate for 15 minutes in the refrigerator (4℃).

6) Wash cells by adding 1-2 mL of buffer per 10 ⁷ cells, and centrifuge at 340×g for 10 minutes. Remove the supernatant completely.

7) Resuspend in 500 μL buffer per 1x10 ⁸ cells.

8) After mounting the column on the MACs separator, rinse the column with 2mL buffer.

9) Loading the resuspended cells into the column.

10) Recover unlabeled cells that have passed through the column, and wash the column with 3×2 mL buffer. Collect the total effluent.

(3) STEP 3: CD56 ⁺ Cell enrichment

1) Measure the number of cells obtained in STEP 2.

2) Centrifuge the cell suspension at 340×g for 10 minutes. Remove the supernatant completely.

3) Resuspend the cell pellet in 80 μL buffer per 10 ⁷ total cells.

4) Add 20 μL CD56 MicroBeads (Miltenyi Biotec, Cat#130-050-401) per 10 ⁷ total cells.

5) Mix well and incubate for 15 minutes in the refrigerator (4℃).

6) Wash cells by adding 1-2 mL of buffer per 10 ⁷ cells, and centrifuge at 340×g for 10 minutes. Remove the supernatant completely.

7) Resuspend in 500 μL buffer per 1x10 ⁸ cells.

8) After mounting the column on the MACs separator, rinse the column with 3mL buffer.

9) Loading the resuspended cells into the column.

10) Reload the cells that have passed through the column 3 times.

11) Remove the column from the separator and place it in a 15ml collection tube.

12) Add 5mL of buffer to the column.

13) Push the plunger strongly into the column to recover magnetically labeled cells.

The total cell number, viability, and isolation yield confirmed in each STEP are shown in Table 3 below.

Total Cell number (X10 ⁶ ) Viability ( % ) Yield ( % ) PBMC 256.8 98.305 N/A CD3 ^- 172.0 99.13 67.0 CD3 ^- CD56 ⁺ 44.4 98.76 17.3

The results of the DO FACS analysis of NK cells isolated as a result of STEP 3 are shown in FIG. 2 .

Example 1-2: Preparation of culture composition and CD3- CD56+ NK cell culture

The basic components of the medium for culturing CD3-CD56+ NK cells are as described in Table 4 below, and the additives for each experimental group are as described in Table 5.

(1) Preparation of culture composition

component Volume Final
Concentration Products manufacturing company Cat.# Badge Basic Ingredients Human AB serum Sigma H4522-100mL 2.5 ml 5% NK MACS supplement Miltenyi Biotec 130-113-102 500 μL One% NK MACS medium Miltenyi Biotec 130-112-968 to 50ml

experimental group NK for cell proliferation
fusion protein NK for cell stimulation bead Comparative Example 1 Fc-IL2WT 1 nM - Comparative Example 2 IL15R-IL15-Fc + Fc-IL2v 1 nM - Comparative Example 3 IL15R-IL15-Fc + Fc-IL2wt 1 nM - Experimental Example 1-1 Fusion protein A 1 nM - Experimental Example 1-2 50nM NK Activation/Expansion Beads (CD2/CD335) 5μL per 1x10 ⁶ NK cells Experimental Example 1-3 50nM - Experimental Example 2-1 Fusion protein B 1 nM - Experimental Example 2-2 50nM NK Activation/Expansion Beads (CD2/CD335) 5μL per 1x10 ⁶ NK cells Experimental Example 2-3 50nM -

(2) NK cell culture

The NK cells (CD3-/CD56+) isolated in Example 1-1 were seeded in a flask or well plate at 1×10 ⁶ cells/mL. A medium composition including the basic medium components and additives of Tables 4 and 5 was dispensed into each well in which the cells were seeded, and cultured at 37° C., 5% CO ₂ conditions. However, the beads for NK cell stimulation in Table 5 (Miltenyi Biotec, Cat# 130-094-483) are added only at the time of initial seeding. Check the number of cells every 2 days from the 6th day of seeding, and if the cells occupy 80% or more of the culture vessel (confluency), 48-well plate, 24-well plate, 12-well plate, 6-well plate, 25T, 75T The culture medium composition for each experimental group was added in the flask order and subcultured, and finally all cells were harvested on the 18th day.

The results of comparing the total cell number and viability of the natural killer cells cultured on days 6, 8, 10, 12, 14, 16, and 18 are shown in Tables 6 to 7 below.

experimental group number of cells Fold 0 days 6 days 8 days 10 days 12 days 14 days 16 days 18 days Comparative Example 1 1.00 0.70 0.88 1.47 1.75 1.40 1.67 1.23 26.37 Comparative Example 2 1.00 0.83 0.89 1.38 1.47 1.29 1.63 1.05 35.72 Comparative Example 3 1.00 0.78 0.96 1.49 1.50 1.07 1.39 0.95 49.34 Experimental Example 1-1 1.00 0.78 0.99 1.57 2.03 1.56 1.79 1.48 79.75 Experimental Example 1-2 1.00 3.17 2.66 3.11 2.50 1.88 1.29 1.69 903.69 Experimental Example 1-3 1.00 1.36 1.99 2.16 2.22 1.50 2.04 1.21 289.86 Experimental Example 2-1 1.00 0.72 0.92 1.77 2.55 1.83 1.72 1.55 74.52 Experimental Example 2-2 1.00 2.92 2.80 3.26 2.23 2.08 2.00 2.01 2519.34 Experimental Example 2-3 1.00 1.38 1.58 2.77 1.72 2.08 1.40 1.44 172.24

experimental group survival rate 0 days 6 days 8 days 10 days 12 days 14 days 16 days 18 days Comparative Example 1 98.76 95.40 95.51 96.59 94.86 94.83 95.90 91.08 Comparative Example 2 98.76 95.68 95.51 96.87 95.23 94.41 96.13 95.88 Comparative Example 3 98.76 95.73 95.83 97.43 94.50 95.88 96.10 90.05 Experimental Example 1-1 98.76 92.54 94.83 97.00 97.25 96.75 96.31 92.22 Experimental Example 1-2 98.76 94.85 95.78 97.49 96.46 97.83 97.15 96.90 Experimental Example 1-3 98.76 94.03 96.25 97.51 97.63 98.22 97.99 96.70 Experimental Example 2-1 98.76 92.06 93.96 95.05 94.89 93.38 95.22 90.04 Experimental Example 2-2 98.76 95.27 96.37 97.61 97.53 98.52 98.21 96.31 Experimental Example 2-3 98.76 92.40 96.44 97.88 96.70 97.95 97.97 96.69

As a result, compared to the culture using Comparative Examples 1, 2, 3, fusion protein A (Experimental Examples 1-1, 1-2, 1-3) and fusion protein B (Experimental Examples 2-1, 2-2, 2- 3), it was confirmed that the proliferation rate and survival rate of natural killer cells were significantly increased regardless of the concentration of the treated material (FIG. 3A).

When cultured using a fusion protein (Example 1-3, 2-3) at a concentration of 50nM compared to culture using a fusion protein at a concentration of 1nM (Experimental Examples 1-1, 2-1), the proliferation rate and survival rate of natural killer cells has increased.

In addition, in the case of culturing with beads for NK cell stimulation (Experimental Examples 1-3, 2-3), the effect on cell proliferation is greater than when the beads are not included (Experimental Examples 1-2, 2-2) It was confirmed that it appeared well (FIG. 3B).

Example 2: cultured NK activation of cells marker Expression confirmation

Example 2-1: CD3- CD56+ NK Cell surface staining

1) Prepare PBMCs or CD3-CD56+ cells at a final concentration of 1-2.5×10 ⁶ cells/mL.

2) Dispense 200μL aliquots of cell suspension (2-5×10 ⁵ cells) into the round bottom-well of the plate.

3) Cells are pelleted by centrifugation at 340×g and 4° C. for 5 minutes.

4) Remove the supernatant and wash the cells in 200 μL cold FACS Buffer.

5) Pellet the cells by centrifugation at 340×g, 4°C for 5 minutes, and remove the supernatant.

6) To block non-specific Fc-mediated interactions, add 50 μL diluted Fc Block (200:1) per well, and incubate at 4°C for 10 minutes.

7) Add the antibody of Table 8 below and fluorescence minus one (FMO) control antibody to the cells, and incubate for 20 minutes on ice protected from light.

8) Wash the cells twice with 200 μL FACS Buffer. Centrifuge the cells at 340 x g for 5 min.

9) Carefully remove the supernatants from the cell pellets.

10) Gently tap the plate to release the cell pellet.

11) Resuspension the cell pellet with 200 μL Fixation Buffer.

12) Analyze stained cell samples by flow cytometry.

Antigen Clone Producer Cat# CD3 HIT3a BioLegend 300326 CD56 B159 BD Pharmingen 557747 CD14 M5E2 BD Pharmingen 557923 CD19 SJ25C1 BD Horizon 563325 CD16 3G8 BD Pharmingen 560195 DNAM-1 DX11 BD Pharmingen 564797 NKG2C 134591 BD OptiBuild 748169 NKG2D 1D11 BD Horizon 562498 NKp46 9E2 BioLegend 331936 CCR5 3A9 BD Pharmingen 550856 NKG2A 131411 BD OptiBuild 747923 TIGIT 741182 BD OptiBuild 747840 CD25 M-A251 BD Horizon 563352 CD57 NK-1 BD Horizon 565285 CD96 6F9 BD Pharmingen 562379

Example 2-2: CD3- CD56+ NK cell intracellular Intracellular staining

1) Prepare PBMCs or CD3-CD56+ cells at a final concentration of 1-2.5×10 ⁶ cells/mL.

2) Dispense 200μL aliquots of cell suspension (2-5×10 ⁵ cells) into round-bottom wells of the plate.

3) Cells are pelleted by centrifugation at 340×g and 4° C. for 5 minutes.

4) To prepare the Stimulating medium, dilute 500X Stimulating cocktail (PMA and ionomycin) to a concentration of 1X in complete medium (200μl/well).

5) Remove the supernatant and resuspension the cells in 200 μL of stimulating medium.

6) Incubate at 37°C, 5% CO ₂ in an incubator for 4 hours.

7) Pellet the cells by centrifugation at 340×g, 4°C for 5 minutes.

8) Remove the supernatant and wash the cells in 200 μL cold FACS Buffer.

9) Pellet the cells by centrifugation at 340×g, 4°C for 5 minutes, and remove the supernatant.

10) To block non-specific Fc-mediated interactions, add 50 μL of diluted Fc Block (200:1) per well, and incubate at 4°C for 10 minutes.

11) For surface staining, the antibody of Table 8 and a fluorescence minus one (FMO) control antibody are added to the cells and incubated on ice protected from light for 20 minutes.

12) Wash the cells twice with 200 μL FACS Buffer. Centrifuge the cells at 340 x g for 5 min.

13) Carefully remove the supernatants from the cell pellets.

14) Gently tap the plate to release the cell pellet.

15) Resuspension each pellet in 100 μL CytoFix/CytoPerm solution.

16) Block light and incubate in refrigerator or ice for 30 minutes.

17) Wash twice with 200 μL of 1X Perm/Wash Buffer.

18) For intracellular staining, the antibody of Table 9 and the fluorescence minus one (FMO) control antibody are added to the cells, and incubated on ice protected from light for 20 minutes.

19) Wash the cells with 200 μL Perm/Wash Buffer. Centrifuge the cells at 340 x g for 5 min.

20) Carefully aspirate the supernatants from the cell pellets.

21) Gently tap the plate to release the cell pellet.

22) Resuspension the cell pellet with 200 μL Fixation Buffer.

23) Analyze stained cell samples by flow cytometry.

Antigen Clone Producer Cat# IFN-gamma 4S.B3 BioLegend 502506 Granzyme B QA16A02 BioLegend 372214 Perforin B-D48 BioLegend 353312

Example 2-3: Cell Characterization (Flow flow cytometry )

After culturing the natural killer cells (CD3-CD56+) cultured with the culture composition of Example 1-2 for 18 days, the purity and expression of activators and inhibitors were confirmed (Tables 10 to 12 and FIGS. 4 to FIGS. 6).

Groups CD16 DNAM -One NKG2C NKG2D NKp46 CCR5 Comparative Example 1 26.50 98.70 2.94 88.30 96.00 44.30 Comparative Example 2 27.60 98.10 4.26 89.20 96.40 49.00 Comparative Example 3 29.40 98.10 4.02 89.80 96.30 47.70 Experimental Example 1-1 28.80 99.10 3.00 87.40 97.30 63.40 Experimental Example 1-2 62.40 97.30 6.11 91.90 93.20 96.80 Experimental Example 1-3 33.90 99.60 1.60 81.30 96.70 73.50 Experimental Example 2-1 33.10 99.70 1.61 83.80 98.40 78.70 Experimental Example 2-2 62.40 98.50 4.64 88.40 94.60 94.70 Experimental Example 2-3 34.30 99.60 1.08 68.20 96.40 58.00

※ Activation marker Expression level (%)

Groups NKG2A TIGIT CD25 CD57 CD96 Comparative Example 1 10.80 14.10 0.39 11.40 91.00 Comparative Example 2 17.30 10.50 0.64 15.00 89.90 Comparative Example 3 16.90 15.30 0.31 12.10 90.10 Experimental Example 1-1 11.00 17.80 0.18 12.60 91.20 Experimental Example 1-2 5.58 39.50 0.65 21.00 87.60 Experimental Example 1-3 7.94 12.80 1.26 29.20 86.10 Experimental Example 2-1 6.85 13.30 0.77 24.70 82.20 Experimental Example 2-2 4.57 35.20 1.60 21.60 82.60 Experimental Example 2-3 5.13 12.00 1.89 33.20 77.20

※ Inhibition marker Expression level (%)

Groups PD-1 Tim-3 IFN -gamma Granzyme B Perforin Comparative Example 1 0.07 0.04 49.30 98.70 95.90 Comparative Example 2 0.03 0.02 56.40 97.40 96.10 Comparative Example 3 0.06 0.39 58.10 98.50 96.70 Experimental Example 1-1 0.03 0.03 51.10 99.10 96.90 Experimental Example 1-2 0.04 0.02 30.30 99.70 96.00 Experimental Example 1-3 0.03 0.01 38.40 99.30 95.50 Experimental Example 2-1 0.01 0.02 54.40 99.40 96.60 Experimental Example 2-2 0.02 0.00 44.30 99.70 96.60 Experimental Example 2-3 0.04 0.04 73.30 98.90 96.60

※ Intracellular marker Expression level (%)

As a result, compared to the natural killer cells cultured in Comparative Examples 1, 2, 3, fusion protein A (Experimental Examples 1-1, 1-2, 1-3) and fusion protein B (Experimental Examples 2-1, 2-2) , 2-3) confirmed that the expression of markers involved in activity and cancer killing in cultured natural killer cells was maintained at an equal level and high, and that the expression of markers involved in inhibition was maintained at an equal level and low. was confirmed (FIG. 5).

In addition, in the case of culturing with beads for NK cell stimulation in the fusion protein (Experimental Examples 1-3, 2-3), compared to natural killer cells cultured without beads (Experimental Examples 1-2, 2-2) It was confirmed that the expression of CD16, NKG2D, and CCR5 was high (FIG. 6).

Example 3: CD3- CD56+ NK cellular cancer cells killing ability Confirm

Example 3-1: Experiment to confirm the cancer cell killing effect

1) Target cells (cancer cells) were stained with 30 μl/mL Calcein-acetoxymethyl (AM) for 1 hour in a CO ₂ incubator.

Cancer cell line information is as described in Table 13 below.

Cancer Cell Origin, Organ Disease K562 Lymphoma Chronic Myelogenous Leukemia (CML) BT-474 Breast Ductal Carcinoma MDA-MB-231 Breast Adenocarcinoma

2) After incubation, the target cells were washed twice with media.

3) Effector cells (NK cells) were prepared according to the appropriate Effector:Target ratio (10:1, 3:1, 1:1).

4) Effector cells were co-cultured in triplicate with target cell lines in a 96 well plate at 37°C and 5% CO ₂ at the corresponding ratio (10:1, 3:1, 1:1) for 4 hours.

5) In order to measure the maximum fluorescence, the stained target cells were treated with Triton-X100, incubated for 4 hours, and spontaneous fluorescence emission was measured by incubating the stained target cells for 4 hours.

6) After 4 hours, centrifugation was performed at 2000 rpm, 3 minutes, and 4°C, and 100 μL supernatant was transferred to a 96 well black plate.

7) Fluorescence was measured with a fluorescence microplate reader at excitation 485 nm and emission 535 nm.

8) The percentage of specific Calcein-AM release was calculated according to the following formula:

% specific release = ((mean experimental release-mean spontaneous release)/(mean maximal release-mean spontaneous release)) × 100

Example 3-2: Confirmation of cancer cell killing effect

After culturing natural killer cells (CD3-CD56+) cultured with the culture composition of Example 1-2 for 18 days, the killing ability against K562, BT-474, and MDA-MB-231 cancer cell lines was confirmed (Table 14). to Table 16).

Groups E10 E3 E1 Comparative Example 1 85.9 72.8 38.7 Comparative Example 2 85.4 69.3 35.7 Comparative Example 3 84.1 70.1 40.8 Example 1-1 95.4 85.3 58.5 Example 1-2 88.0 85.7 54.5 Examples 1-3 93.5 82.7 46.6 Example 2-1 96.1 86.6 50.8 Example 2-2 96.6 88.3 56.2 Example 2-3 90.4 64.6 30.7

※ K562 Lysis (%)

Groups E10 E3 E1 Comparative Example 1 57.8 46.0 27.5 Comparative Example 2 62.4 44.5 30.4 Comparative Example 3 60.2 43.4 27.3 Example 1-1 69.8 62.4 42.7 Example 1-2 76.1 67.4 44.7 Examples 1-3 92.9 75.9 42.8 Example 2-1 83.9 76.3 41.0 Example 2-2 86.9 76.7 43.9 Example 2-3 64.3 39.4 22.1

※ BT-474 Lysis (%)

Groups E10 E3 E1 Comparative Example 1 68.3 42.5 16.8 Comparative Example 2 66.3 37.9 15.1 Comparative Example 3 61.7 34.5 15.7 Example 1-1 69.5 41.8 21.3 Example 1-2 79.9 57.8 26.8 Examples 1-3 89.8 63.9 29.2 Example 2-1 82.1 52.9 22.8 Example 2-2 89.1 64.9 32.7 Example 2-3 67.8 30.2 10.8

※ MDA-MB-231 Lysis (%)

As a result, in all Effector: Target conditions (E10, E3, E1), fusion protein A (Examples 1-1, 1-2, 1-3) and fusion protein B (Examples 2-1, 2-2, 2) It was confirmed that the cancer cell killing ability of the natural killer cells cultured by treatment with -3) was better than the cancer cell killing ability of the natural killer cells cultured by treating Comparative Examples 1, 2 and 3. In addition, in the case of culturing with beads for NK cell stimulation in the fusion protein (Experimental Examples 1-3, 2-3), higher than that of natural killer cells cultured without beads (Experimental Examples 1-2, 2-2) A cancer-killing effect was confirmed.

As the specific parts of the present invention have been described in detail above, for those of ordinary skill in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. will be. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.

<110> GI Cell, Inc. <120> Fusion Protein Comprising IL15 protein, IL15 receptor alpha protein, Fc domain and IL12 Protein And Uses Thereof <130> P21-B209 <150> KR 2020-0109995 <151> 2020-08-31 <160> 13 <170> KoPatentIn 3.0 <210> 1 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Human IL15 <400> 1 Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 1 5 10 15 Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 20 25 30 Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 35 40 45 Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 50 55 60 Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 65 70 75 80 Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 85 90 95 Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 100 105 110 Thr Ser <210> 2 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Linker 1 <400> 2 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Se r Gly 1 5 10 15 Gly Gly Gly Ser 20 <210> 3 <211> 78 <212> PRT <213> Artificial Sequence <220> <223> Human IL15Ra Sushi domain <400> 3 Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 1 5 10 15 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 20 25 30 Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 35 40 45 Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 50 55 60 Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser 65 70 75 <210> 4 <211> 28 <212> PRT <213 > Artificial Sequence <220> <223> Linker 2 <400> 4 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala 1 5 10 15 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro 20 25 < 210> 5 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> IgG4 Fc <400> 5 Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp V al Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met 115 120 125 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155 160 Tyr Lys Thr Thr Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175 Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Hi s Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Leu Gly 210 215 <210> 6 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Linker 3 <400> 6 Gly Gly Gly Gly Ser 1 5 <210> 7 <211> 133 <212> PRT <213> Artificial Sequence <220> <223> Human IL2(WT) <400> 7 Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 1 5 10 15 Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 20 25 30 Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys 35 40 45 Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 50 55 60 Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 65 70 75 80 Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 85 90 95 Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 100 105 110 Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 115 120 125 Ile Ser Thr Leu Thr 130 <210> 8 <211> 133 <212> PRT <213> Artificial Sequence <220> <223> Human IL2(Mutant) <400> 8 Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 1 5 10 15 Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 20 25 30 Asn Pro Lys Leu Thr Ala Met Leu Thr Ala Lys Phe Tyr Met Pro Lys 35 40 45 Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 50 55 60 Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 65 70 75 80 Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 85 90 95 Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 100 105 110 Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 115 120 125 Ile Ser Thr Leu Thr 130 <210> 9 <211> 594 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein A <400> 9 Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 1 5 10 15 Gln Ser Met HisIle Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 20 25 30 Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 35 40 45 Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 50 55 60 Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 65 70 75 80 Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 85 90 95 Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 100 105 110 Thr Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Ile Thr Cys Pro Pro Pro Met Ser Val Glu 130 135 140 His Ala Asp Ile Trp Val Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg 145 150 155 160 Tyr Ile Cys Asn Ser Gly Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu 165 170 175 Thr Glu Cys Val Leu Asn Lys Ala Thr Asn Val Ala His Trp Thr Thr 180 185 190 Pro Ser Leu Lys Cys Ile Arg Asp Pro Ala Leu Val His Gln Arg Pro 195 200 205 Ala Pro Pro Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 210 215 220 Gly Gly Ser Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro 225 230 235 240 Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 245 250 255 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 260 265 270 Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 275 280 285 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 290 295 300 Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 305 310 315 320 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 325 330 335 Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 340 345 350 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met 355 360 365 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 370 375 380 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 385 390 395 400 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 405 410 415 Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val 420 425 430 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 435 440 445 Lys Ser Leu Ser Leu Ser Leu Gly Gly Gly Gly Gly Ser Ala Pro Thr 450 455 460 Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu 465 470 475 480 Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys 485 490 495 Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr 500 505 510 Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu 515 520 525 Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg 530 535 540 Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser 545 550 555 560 Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val 565 570 575 Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr 580 585 590 Leu Thr <210> 10 <211> 594 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein B <400> 10 Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 1 5 10 15 Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 20 25 30 Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 35 40 45 Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 50 55 60 Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 65 70 75 80 Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 85 90 95 Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 100 105 110 Thr Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Gly Ser Ile Thr Cys Pro Pro Pro Met Ser Val Glu 130 135 140 His Ala Asp Ile Trp Val Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg 145 150 155 160 Tyr Ile Cys Asn Ser Gly Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu 165 170 175 Thr Glu Cys Val Leu Asn Lys Ala Thr Asn Val Ala His Trp Thr Thr 180 185 190 Pro Ser Leu Lys Cys Ile Arg Asp Pro Ala Leu Val His Gln Arg Pro 195 200 205 Ala Pro Pro Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 210 215 220 Gly Gly Ser Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro 225 230 235 240 Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 245 250 255 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 260 265 270 Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 275 280 285 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 290 295 300 Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 305 310 315 320 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 325 330 335 Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 340 345 350 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met 355 360 365 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 370 375 380 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 385 390 395 400 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 405 410 415 Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val 420 425 430 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 435 440 445 Lys Ser Leu Ser Leu Ser Leu Gly Gly Gly Gly Gly Ser Ala Pro Thr 450 455 460 Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu 465 470 475 480 Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys 485 490 495 Leu Thr Ala Met Leu Thr Ala Lys Phe Tyr Met Pro Lys Lys Ala Thr 500 505 510 Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu 515 520 525 Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg 530 535 540 Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser 545 550 555 560 Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val 565 570 575 Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr 580 585 590 Leu Thr <210> 11 <211> 1855 < 212> DNA <213> Artificial Sequence <220> <223> Fusion protein A <400> 11 gccaccatga agtgggtcac cttcatctcc ctgctgtttc tgttctcct c cgcctactcc 60 aactgggtca acgtgatctc cgacctgaag aagatcgagg acctgatcca gtccatgcac 120 atcgacgcta ccctgtacac cgagtccgat gtgcaccctt cttgcaaagt gaccgctatg 180 aagtgcttcc tgctggaact gcaagtgatc tccctggaat ccggcgacgc ctctatccac 240 gataccgtgg aaaacctgat catcctggcc aacaactccc tgtcctccaa cggcaatgtg 300 accgagtctg gctgcaaaga gtgcgaggaa ctggaagaga agaacatcaa agagttcctc 360 cagtccttcg tccacatcgt gcagatgttc atcaacacct ctggcggcgg aggaagtggt 420 ggcggaggat ctggcggtgg tggttctggc ggaggcggat ctattacctg tccacctcct 480 atgtccgtgg aacacgccga catctgggtc aagtcctaca gcctgtactc cagagagcgg 540 tacatctgca actccggctt caagagaaag gccggcacat cttctctgac cgagtgcgtg 600 ctgaacaagg ccaccaatgt ggctcactgg accacaccta gcctgaagtg catcagagat 660 cccgctctgg tccatcagag gcctgctcct ccaagcggtg gtggtggaag cggaggtggc 720 ggatcaggtg gtggcggttc tgctgagtct aagtacggac ctccttgtcc accttgtcct 780 gctccagaag ctgctggcgg accaagcgtt ttcctgtttc ctccaaagcc taaggacacc 840 ctgatgatct ctcggacccc tgaagtgacc tgcgtggtgg tcgatgtgtc tcaagaggac 900 ccg aggtgc agttcaattg gtacgtggac ggcgtggaag tgcacaacgc caagaccaag 960 cctagagagg aacagttcaa ctccacctac agagtggtgt ccgtgctgac cgtgctgcac 1020 caggattggc tgaacggcaa agagtacaag tgcaaggtgt ccaacaaggg cctgccttcc 1080 agcatcgaaa agaccatctc caaggctaag ggccagcctc gggaacctca ggtttacacc 1140 ctgcctccaa gccaagagga aatgaccaag aaccaggtgt ccctgacctg cctggtcaag 1200 ggcttctacc cttccgatat cgccgtggaa tgggagtcca atggccagcc tgagaacaac 1260 tacaagacaa cccctcctgt gctggactcc gacggctcct tttttctgta ctcccgcctg 1320 accgtggaca agtccagatg gcaagagggc aacgtgttct cctgctctgt gatgcacgag 1380 gccctgcaca accactacac ccagaagtcc ctgtctctgt ctcttggagg cggtggcgga 1440 agtgctccta cctccagctc taccaagaaa acccagctgc agttggagca tctgctgctg 1500 gacctccaga tgatcctgaa tggcatcaac aattacaaga accccaagct gacccggatg 1560 ctgaccttca agttctacat gcccaagaag gccaccgagc tgaagcacct ccagtgcctg 1620 gaagaggaac tgaagcccct ggaagaagtg ctgaatctgg cccagtccaa gaacttccac 1680 ctgaggcctc gggatctgat ctccaacatc aatgtgatcg tgttggagct gaagggctcc 1740 gagacaacct tcatgtgcga gtacgccgac gagacagcca ccatcgtgga atttctgaac 1800 cggtggatca ccttctgcca gtccatcatc tccacactga cctgatgact cgaga 1855 <210> 12 <211> 1842 <212> DNA <213> Artificial Sequence <220> <223> Fusion protein ttat gct <213> aactgggtca acgtgatctc cgacctgaag aagatcgagg acctgatcca gtccatgcac 120 atcgacgcta ccctgtacac cgagtccgac gtgcaccctt cctgtaaagt gaccgccatg 180 aagtgctttc tgctggaact gcaagtgatc tccctggaat ccggcgacgc ctctatccac 240 gacaccgtgg aaaacctgat catcctggcc aacaactccc tgtcctccaa cggcaacgtg 300 accgagtctg gctgcaaaga gtgcgaggaa ctggaagaga agaacatcaa agagttcctc 360 cagtccttcg tgcacatcgt gcagatgttc atcaacacct ctggcggcgg aggatctggc 420 ggaggtggaa gcggaggcgg aggtagcggt ggtggtggat ctatcacatg ccctccacct 480 atgtccgtgg aacacgccga catctgggtc aagtcctaca gcctgtactc cagagagcgg 540 tacatctgca actccggctt caagagaaag gccggcacct ctagcctgac cgagtgcgtg 600 ctgaacaagg ccaccaatgt ggcccactgg cccaccctg catgcctgaagtg ttcatcagag gcctgctcca cctagtggtg gcggtggtag tggcggaggc 720 ggttcaggtg gcggcggatc tgctgagtct aagtacggac ctccttgtcc accttgtcct 780 gctccagaag ctgctggcgg cccttccgtg tttctgttcc ctccaaagcc taaggacacc 840 ctgatgatct ctcggacccc tgaagtgacc tgcgtggtgg tcgatgtgtc ccaagaggat 900 cccgaggtgc agttcaattg gtacgtggac ggcgtggaag tgcacaacgc caagaccaag 960 cctagagagg aacagttcaa ctccacctac agagtggtgt ccgtgctgac cgtgctgcac 1020 caggattggc tgaacggcaa agagtacaag tgcaaggtgt ccaacaaggg cctgccttcc 1080 agcatcgaaa agaccatctc caaggccaag ggccagccta gggaacccca ggtttacacc 1140 ctgcctccaa gccaagagga aatgaccaag aaccaggtgt ccctgacctg cctggtcaag 1200 ggcttctacc cttccgatat cgccgtggaa tgggagagca atggccagcc tgagaacaac 1260 tacaagacaa cccctcctgt gctggactcc gacggctcct tctttctgta ctcccgcctg 1320 accgtggaca agtccagatg gcaagagggc aacgtgttct cctgctccgt gatgcacgag 1380 gccctgcaca atcactacac ccagaagtcc ctgtctctgt cccttggagg tggtggtggc 1440 tctgctccta cctcctccag caccaagaaa acccagctgc agttggagca tctgctgctg 1500 gacctccaga tgatcctgaa tggcatcaac aattacaaga accccaagct caccgccatg 1560 ctgaccgcca agttctacat gcccaagaag gccaccgagc tgaagcacct ccagtgcctg 1620 gaagaggaac tgaagcccct ggaagaagtg ctgaatctgg cccagtccaa gaacttccac 1680 ctgaggcctc gcgacctgat ctccaacatc aatgtgatcg tgttggagct gaagggctcc 1740 gagacaa cct tcatgtgcga gtacgccgac gagacagcta ccatcgtgga atttctgaac 1800 cggtggatca ccttctgcca gtccatThrcatc tccacactga cc 1842 <210> 13 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Phe Albumin Signal Sequence <400 Ser Leu Leu Phe Leu Phe Ser Ser Ala 1 5 10 15Tyr Ser

Claims (23)

A fusion protein comprising an IL15 protein, an IL15 receptor alpha (IL15Rα) protein, an Fc domain and an IL2 protein.
The fusion protein according to claim 1, wherein the IL15 protein comprises the amino acid sequence represented by SEQ ID NO: 1.
The fusion protein according to claim 1, wherein the IL15 receptor alpha (IL15Rα) protein comprises the amino acid sequence shown in SEQ ID NO: 3.
The fusion protein according to claim 1, wherein the Fc domain comprises an immunoglobulin heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3).
The fusion protein according to claim 4, wherein the immunoglobulin is IgG, IgA, IgE, IgD or IgM.
The fusion protein according to claim 4, wherein the Fc domain comprises the amino acid sequence represented by SEQ ID NO: 5.
The fusion protein according to claim 1, wherein the IL2 protein is wild-type or mutant.
The fusion protein according to claim 7, wherein the IL2 protein comprises an amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 8.
The fusion protein according to claim 1, wherein the fusion protein is composed of the following structural formula (I):
N'-X-[Linker(1)]lY-[Linker(2)]n-Fc domain-[Linker(3)]mZC' (Structure (I))
here,
N' is the N-terminus of the fusion protein, C' is the C-terminus of the fusion protein,
X is an IL15 protein, Y is an IL15 receptor alpha (IL15Rα) protein, Z is an IL2 protein,
Linker (1), linker (2) and linker (3) are peptide linkers,
l, n and m are each independently O or 1.
The fusion protein according to claim 9, wherein the linker (1) comprises the amino acid sequence represented by SEQ ID NO: 2.
The fusion protein according to claim 9, wherein the linker (2) comprises the amino acid sequence shown in SEQ ID NO: 4.
The fusion protein according to claim 9, wherein the linker (3) comprises the amino acid sequence shown in SEQ ID NO: 6.
The fusion protein according to claim 1, wherein the fusion protein comprises the amino acid sequence represented by SEQ ID NO: 9 or SEQ ID NO: 10.
A polynucleotide encoding the fusion protein of any one of claims 1 to 13.
A vector comprising the polynucleotide of claim 14 .
A transformed cell into which the vector of claim 15 is introduced.
A method for producing a fusion protein comprising the step of culturing the transformed cell of claim 16 .
A fusion protein dimer in which two fusion proteins of claim 1 are combined.
The fusion protein dimer according to claim 18, wherein the fusion protein dimer is a homodimer.
A composition for culturing NK cells (natural killer cell) comprising the dimer of any one of claims 1 to 13 or the fusion protein of claim 18.
A method for culturing NK cells (natural killer cells) comprising the step of culturing NK cells in a medium containing the composition of claim 20.
22. The method of claim 21,
(a) isolating cells that do not express CD3 from peripheral blood mononuclear cells (PBMCs);
(b) separating the cells expressing CD56 from the cells isolated in step (a); and
(c) culturing the cells isolated in step (b) in the presence of the composition of claim 20;
NK cell (natural killer cell) culture method comprising a.
A composition for treating cancer, immune disease, or infectious disease comprising NK cells prepared by the NK cell (natural killer cell) culture method of claim 21.

Images